• Content
  • Search
  • Navigation
  • Sitemap
  • About us
    • About us
    • Who we are
    • Our model
    • Data driven investment process
    • Our purpose, culture and values
    • Our history
  • Our people
    • Our people
    • Board of directors
  • Portfolio
    • Portfolio
    • Cell therapy
      • Overview
      • Autolus
      • Achilles Therapeutics
      • Quell Therapeutics
      • Resolution Therapeutics
      • Neogene Therapeutics
      • Clade Therapeutics
    • Gene therapy
      • Overview
      • Freeline Therapeutics
      • SwanBio Therapeutics
      • Purespring Therapeutics
    • Biologics
      • Overview
      • Anaveon
    • Small molecule
      • Overview
      • OMass Therapeutics
    • Previous investments
      • Overview
      • Gyroscope Therapeutics
      • Blue Earth
      • Nightstar
      • 14MG
      • Azeria Therapeutics
  • Sustainability
    • Sustainability
    • Message from Chief Executive, SIML
    • Our approach to sustainability reporting
    • Our social impact
    • Responsible investor and partner
      • Overview
      • Responsible investment process
      • A responsible partner
      • Sustainability within the Syncona portfolio
    • Inspiring and empowering our people
    • Responsible and ethical business
      • Overview
      • Environment
      • Syncona TCFD disclosure
    • Syncona’s approach to charity
      • Overview
      • The Syncona Foundation
    • Sustainability policies
  • News and Insights
  • Investors
    • Investors
    • Investment proposition
    • KPIs
    • Results and presentations
    • RNS and inside information
    • Share price centre
    • Governance
      • Overview
      • Our Committees
      • How we communicate with our stakeholders
    • Regulatory publications
    • Financial calendar
    • Analysts and advisers
    • Shareholder information
      • Overview
      • Shareholder documents
    • FAQs
  • Contact

News

Show
  • Sustainability
  • Financial
  • Operating News
news from
  • all companies
  • Syncona
  • all Cell therapy companies
  • Autolus
  • Achilles Therapeutics
  • Quell Therapeutics
  • Resolution Therapeutics
  • Neogene Therapeutics
  • Clade Therapeutics
  • all Gene therapy companies
  • Freeline Therapeutics
  • SwanBio Therapeutics
  • Purespring Therapeutics
  • all Biologics companies
  • Anaveon
  • all Small molecule companies
  • OMass Therapeutics
30.06.22

Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board

  • Operating News
  • Cell therapy
  • Achilles Therapeutics
21.06.22

Achilles Therapeutics Recognized with the 2022 PING Innovation Award

  • Cell therapy
  • Achilles Therapeutics
10.05.22

Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

  • Cell therapy
  • Achilles Therapeutics
09.05.22

Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma

  • Operating News
  • Cell therapy
  • Achilles Therapeutics
04.05.22

Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors

  • Operating News
  • Cell therapy
  • Achilles Therapeutics
03.05.22

Achilles to present at upcoming conferences

  • Operating News
  • Cell therapy
  • Achilles Therapeutics
Load more

Sign-up for company news alerts

Get the latest RNS, company news, share price information and results from Syncona

  • RNS alerts
  • Company alerts

Syncona Investment Management Limited
2nd Floor
8 Bloomsbury Street
London
WC1B 3SR
contact@synconaltd.com

  • About us
  • Our people
  • Portfolio
  • Sustainability
  • News and Insights
  • Investors
  • Contact
  • Copyright © Syncona 2022
  • Accessibility
  • Privacy & cookies
  • Employee privacy notice
  • Third party privacy notice
  • Regulatory publications
  • Modern Slavery Statement

Syncona Limited is registered in Guernsey no. 55514, registered office Arnold House, PO Box 273, St Julian’s Avenue, St Peter Port, Guernsey GY1 3RD.
Syncona Investment Management Limited is registered in England no. 10497864, 8 Bloomsbury Street, London WC1B 3SR and is authorised and regulated by the FCA. Syncona Limited is managed by Syncona Investment Management Limited.

Designed & built by SampsonMay
  • About us
    • About us
    • Who we are
    • Our model
    • Data driven investment process
    • Our purpose, culture and values
    • Our history
  • Our people
    • Our people
    • Board of directors
  • Portfolio
    • Portfolio
    • Cell therapy
      • Overview
      • Autolus
      • Achilles Therapeutics
      • Quell Therapeutics
      • Resolution Therapeutics
      • Neogene Therapeutics
      • Clade Therapeutics
    • Gene therapy
      • Overview
      • Freeline Therapeutics
      • SwanBio Therapeutics
      • Purespring Therapeutics
    • Biologics
      • Overview
      • Anaveon
    • Small molecule
      • Overview
      • OMass Therapeutics
    • Previous investments
      • Overview
      • Gyroscope Therapeutics
      • Blue Earth
      • Nightstar
      • 14MG
      • Azeria Therapeutics
  • Sustainability
    • Sustainability
    • Message from Chief Executive, SIML
    • Our approach to sustainability reporting
    • Our social impact
    • Responsible investor and partner
      • Overview
      • Responsible investment process
      • A responsible partner
      • Sustainability within the Syncona portfolio
    • Inspiring and empowering our people
    • Responsible and ethical business
      • Overview
      • Environment
      • Syncona TCFD disclosure
    • Syncona’s approach to charity
      • Overview
      • The Syncona Foundation
    • Sustainability policies
  • News and Insights
  • Investors
    • Investors
    • Investment proposition
    • KPIs
    • Results and presentations
    • RNS and inside information
    • Share price centre
    • Governance
      • Overview
      • Our Committees
      • How we communicate with our stakeholders
    • Regulatory publications
    • Financial calendar
    • Analysts and advisers
    • Shareholder information
      • Overview
      • Shareholder documents
    • FAQs
  • Contact
GBX 201.50
Change: -3.00 (-1.47%)

Search